|
US20020183276A1
(en)
|
2001-03-23 |
2002-12-05 |
Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
|
US20030078232A1
(en)
|
2001-08-08 |
2003-04-24 |
Elfatih Elzein |
Adenosine receptor A3 agonists
|
|
EP1465634B1
(en)
|
2001-12-12 |
2014-10-22 |
The Government of the United States of America, as represented by the Secretary Department of Health and Human Services |
Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
|
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
US20090142347A1
(en)
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
JP2009519236A
(ja)
|
2005-11-30 |
2009-05-14 |
キャン−ファイト・バイオファーマ・リミテッド |
Ａ３アデノシンレセプター抗体の治療的使用
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2238170B1
(en)
|
2008-01-31 |
2016-11-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
SMT202000031T1
(it)
|
2010-06-09 |
2020-03-13 |
Genmab As |
Anticorpi contro cd38 umano
|
|
WO2012031008A2
(en)
|
2010-08-31 |
2012-03-08 |
The General Hospital Corporation |
Cancer-related biological materials in microvesicles
|
|
WO2012031320A1
(en)
*
|
2010-09-06 |
2012-03-15 |
Peter Maccallum Cancer Institute |
Cancer diagnostic
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
EP2654789B1
(en)
|
2010-12-22 |
2018-05-30 |
Orega Biotech |
Antibodies against human cd39 and use thereof
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
JP6302846B2
(ja)
|
2012-02-22 |
2018-03-28 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9307487B2
(en)
|
2013-08-30 |
2016-04-05 |
Qualcomm Incorporated |
Methods and systems for improved utilization of a wireless medium
|
|
MA39986A
(fr)
|
2014-04-25 |
2017-03-01 |
Vitae Pharmaceuticals Inc |
Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
|
|
GB2537445A
(en)
|
2014-11-10 |
2016-10-19 |
Medimmune Ltd |
Binding molecules specific for CD73 and uses thereof
|
|
GB2538120A
(en)
*
|
2014-11-11 |
2016-11-09 |
Medimmune Ltd |
Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
CA3005986A1
(en)
|
2015-11-23 |
2017-06-01 |
Innate Pharma |
Cd39 vascular isoform targeting agents
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
WO2017120508A1
(en)
|
2016-01-08 |
2017-07-13 |
Arcus Biosciences, Inc. |
Modulators of 5'-nucleotidase, ecto and the use thereof
|
|
EP3423494A1
(en)
*
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
EP3518934A4
(en)
*
|
2016-10-03 |
2020-06-24 |
Arcus Biosciences, Inc. |
Inhibitors of adenosine 5'-nucleotidase
|
|
WO2018094148A1
(en)
|
2016-11-18 |
2018-05-24 |
Arcus Biosciences, Inc. |
Inhibitors of cd73-mediated immunosuppression
|
|
KR102638592B1
(ko)
|
2016-12-22 |
2024-02-19 |
안텐진 테라퓨틱스 리미티드 |
엑토뉴클레오티다제 억제제 및 이의 용도
|
|
US10624968B2
(en)
*
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
|
HUE064141T2
(hu)
|
2017-01-20 |
2024-02-28 |
Arcus Biosciences Inc |
Azolopirimidin rákkal összefüggõ rendellenességek kezelésére
|
|
CA3045376C
(en)
|
2017-01-24 |
2022-08-30 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
|
EP3600273A4
(en)
|
2017-03-31 |
2021-01-20 |
Peloton Therapeutics, Inc. |
CD73 INHIBITORS AND USES THEREOF
|
|
EP3606531A4
(en)
|
2017-04-04 |
2021-04-28 |
Corvus Pharmaceuticals, Inc. |
METHOD OF TREATMENT OF CANCER
|
|
US20190022096A1
(en)
|
2017-04-04 |
2019-01-24 |
Corvus Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
US20210107989A1
(en)
|
2017-04-04 |
2021-04-15 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
|
ES2953349T3
(es)
|
2017-05-05 |
2023-11-10 |
Arcus Biosciences Inc |
Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer
|
|
WO2018208727A1
(en)
|
2017-05-08 |
2018-11-15 |
Eternity Bioscience Inc. |
Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
|
|
WO2018208980A1
(en)
|
2017-05-10 |
2018-11-15 |
Oric Pharmaceuticals, Inc. |
Cd73 inhibitors
|
|
PL3634417T3
(pl)
|
2017-05-17 |
2023-09-25 |
Arcus Biosciences, Inc. |
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
|
|
CN110997722B
(zh)
|
2017-06-08 |
2023-09-26 |
黑带医疗有限公司 |
Cd38调节抗体
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
CN107286146B
(zh)
|
2017-07-05 |
2020-07-31 |
上海肇钰医药科技有限公司 |
作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
|
|
WO2019023635A1
(en)
|
2017-07-27 |
2019-01-31 |
Stingray Therapeutics, Inc. |
SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
|
|
KR102770110B1
(ko)
|
2017-08-16 |
2025-02-20 |
블랙 벨트 테라퓨틱스 리미티드 |
Cd38 항체
|
|
CA3073085A1
(en)
|
2017-08-16 |
2019-02-21 |
Black Belt Therapeutics Limited |
Cd38 modulating antibody
|
|
KR20200096921A
(ko)
|
2017-11-06 |
2020-08-14 |
코버스 파마슈티칼스, 인크. |
암 치료를 위한 아데노신 경로 억제제
|
|
CA3090922A1
(en)
|
2018-02-16 |
2019-08-22 |
Arcus Biosciences, Inc. |
Dosing with an azolopyrimidine compound
|
|
TWI702954B
(zh)
|
2018-03-01 |
2020-09-01 |
美商美國禮來大藥廠 |
Cd73抑制劑
|
|
CN112004541A
(zh)
|
2018-03-09 |
2020-11-27 |
艾库斯生物科学有限公司 |
肠道外给药的免疫增强药物
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
TW202012637A
(zh)
*
|
2018-04-24 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
治療癌症之方法
|
|
EP3823614A4
(en)
|
2018-07-18 |
2022-03-30 |
Arcus Biosciences, Inc. |
SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
|
|
PL3829581T3
(pl)
|
2018-07-27 |
2024-07-01 |
Arcus Biosciences, Inc. |
Antagoniści pirydonu a2r
|
|
WO2020046813A1
(en)
|
2018-08-27 |
2020-03-05 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
CA3115607A1
(en)
|
2018-10-11 |
2020-04-16 |
Pfizer Inc. |
Dosage regimen for tfpi antagonists
|
|
EP3893891A4
(en)
|
2018-12-13 |
2022-08-03 |
Arcus Biosciences, Inc. |
SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
|
|
CN113795267A
(zh)
|
2019-03-12 |
2021-12-14 |
艾库斯生物科学有限公司 |
致癌基因驱动的癌症的治疗
|
|
WO2020205527A1
(en)
|
2019-03-29 |
2020-10-08 |
Arcus Biosciences, Inc. |
Treatment of cancer utilizing an identified adenosine fingerprint
|
|
TW202135823A
(zh)
*
|
2020-01-03 |
2021-10-01 |
美商英塞特公司 |
Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
|
|
US11633416B1
(en)
|
2020-03-06 |
2023-04-25 |
Arcus Biosciences, Inc. |
Oral formulations of CD73 compounds
|
|
KR20230026312A
(ko)
|
2020-06-17 |
2023-02-24 |
아르커스 바이오사이언시즈 인코포레이티드 |
Cd73 억제제의 결정형 및 이의 용도
|